Lonza Group Ltd
1LONN
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
19,299
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,290.60 | 6.80 | 0.07% |
| CAC 40 | 8,174.20 | 14.39 | -0.18% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,354.57 | 81.52 | -0.86% |
| HKSE | 25,766.24 | 519.14 | 2.06% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 48,846.69 | 1,264.54 | 2.66% |
| NZX 50 Index | 13,301.09 | 11.88 | 0.09% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,994.30 | 6.10 | 0.07% |
| SSE Composite Index | 3,862.60 | 22.84 | 0.59% |